Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02295683
Other study ID # T124E2
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 2014
Est. completion date September 4, 2017

Study information

Verified date October 2019
Source Terumo Europe N.V.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to document safety and efficacy of renal sympathetic denervation treatment in subjects with uncontrolled hypertension by using Iberis renal denervation system.


Description:

This study is a prospective, multi-center, single-arm, non-interventional and open-label registry to collect descriptive data from patients who receive renal sympathetic denervation treatment in accordance with routine hospital practice using Iberis system.

This registry will collect data prospectively from patients that receive renal sympathetic denervation treatment with use of Iberis renal denervation system and treatment will be applied according to the routine hospital practice. No additional tests are required specific to this registry. The registry will serve as a tool to collect clinical data in order to expand the knowledge base of safety, efficacy and functionality of the Iberis system in patients with resistant hypertension.

A minimum of 30 patients will be enrolled in Europe


Recruitment information / eligibility

Status Terminated
Enrollment 18
Est. completion date September 4, 2017
Est. primary completion date November 30, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age =18 years or minimum age as required by local regulations.

- Patient has been thoroughly informed about this registry and signed Informed Consent Form.

- Patient with true resistant hypertension defined as:

- Office systolic BP higher than 160 or 150mmHg in case of type 2 diabetes

- Ambulatory BP with average BP>130mmHg or mean daytime>135mmHg in more than 70% of the measurements.

- Patients should be on stable hypertension therapy for at least 8 weeks before procedure, including spironolactone if they are supposed to be respondent as indicated by the specialized center/excellence unit on hypertension.

Exclusion Criteria:

- Previous renal artery intervention (balloon angioplasty or stenting).

- Evidence of renal artery atherosclerosis (defined as a renal artery stenosis >50%).

- Main renal arteries of less than 4mm diameter or less than 20mm in length.

- Presence of multiple main renal arteries in either kidney.

- Estimated glomerular filtration rate <45ml/min per 1,73m2

- Recent myocardial infarction, unstable angina pectoris or cerebrovascular accident within the past 3-6 months.

- False resistant hypertension (pseudo resistance) by using 24h ambulatory BP monitoring (ABPM).

- Secondary arterial hypertension.

- Pregnancy.

- There is another pathological process with well-known life expectancy of less than 5 years.

- Patient unable to do correct FU.

- Unable to take correct ambulatory BP.

- Primary hyperaldosteronism.

- Known lack of adherence to medical treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Renal Denervation


Locations

Country Name City State
Serbia Clinical Center of Serbia Belgrade
Spain Hospital Galdakao Galdakao

Sponsors (1)

Lead Sponsor Collaborator
Terumo Europe N.V.

Countries where clinical trial is conducted

Serbia,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood Pressure (BP) Measurements Office BP; Ambulatory BP; Home BP Up to 5 year FU
See also
  Status Clinical Trial Phase
Recruiting NCT05545059 - Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension Phase 3
Not yet recruiting NCT04388124 - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION Phase 2
Withdrawn NCT01939392 - Rapid Renal Sympathetic Denervation for Resistant Hypertension II Phase 2/Phase 3
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting NCT05563077 - Aerobic Exercise and Resistant Hypertension N/A
Recruiting NCT03758196 - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) N/A
Active, not recruiting NCT03179800 - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ N/A
Completed NCT04519658 - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) Phase 2
Not yet recruiting NCT05552300 - Superselective Adrenal Arterial Embolization for Resistant Hypertension N/A
Not yet recruiting NCT05426707 - Remote Ischemic Conditioning for the Treatment of Resistant Hypertension N/A
Completed NCT04345198 - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension N/A
Active, not recruiting NCT05562934 - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. Phase 2
Recruiting NCT06034743 - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3
Withdrawn NCT02926495 - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension. N/A
Active, not recruiting NCT02670681 - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects N/A
Completed NCT02572024 - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study) N/A
Completed NCT02001350 - Carotid Ultrasound Study N/A
Recruiting NCT04331691 - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension Phase 4
Recruiting NCT04637152 - Sacubitril/Valsartan in Resistant Hypertension Phase 2